Indication to cardioverter-defibrillator therapy and outcome in real world primary prevention. Data from the IRIDE [Italian registry of prophylactic implantation of defibrillators] study

Alessandro Proclemer, Daniele Muser, Andrea Campana, Massimo Zoni-Berisso, Massimo Zecchin, Alessandro Locatelli, Marco Brieda, Lorena Gramegna, Mauro Santarone, Leandro Chiodi, Patrizio Mazzone, Luca Rebellato, Domenico Facchin

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Aims: Several trials demonstrated the life saving role of implantable cardioverter-defibrillators (ICD) in primary prevention of sudden cardiac death (SCD). The aim was to evaluate the clinical characteristics and 4-year outcome of consecutive patients treated in clinical practice by prophylactic ICD implantation on the basis of class I recommendations and up-to-date ICD programming. Methods and results: IRIDE multi-center, prospective and observational study enrolled 604 consecutive patients (mean age: 66±10 years) treated by ICD between 01/01/2006 and 30/06/2010. Main characteristics were similarly distributed among the inclusion criteria of MADIT II (24%), SCD-HeFT (24%), COMPANION (26%) and MADIT-CRT (18%) trials, while a small number of patients met the MUSTT and MADIT (7%) inclusion criteria. Single-chamber ICDs were implanted in 168 (28%) patients, dual-chamber in 167 (28%) and biventricular in 269 (43%) patients. ATP programming was activated in 546 (90%) patients. Overall survival and rate of appropriate ICD intervention by ATP and/or shock at 12-24-36-48 months of follow-up were 94%, 89%, 80%, 75% and 16%, 28%, 37% and 50%, respectively. No difference inmortality rate between the groups who received or did not receive appropriate ICD interventions was demonstrated (p=ns). Conclusions: The IRIDE study confirms the effectiveness in real world practice of ICD implantation in patients at risk of SCD. The life saving role of ICD therapy increases as the duration of follow-up is prolonged and the survival benefit is similar in patients who received or did not receive appropriate device treatment, thus suggesting a beneficial effect of up-to-date device programming.

Original languageEnglish
Pages (from-to)1416-1421
Number of pages6
JournalInternational Journal of Cardiology
Volume168
Issue number2
DOIs
Publication statusPublished - Sep 30 2013

Fingerprint

Defibrillators
Implantable Defibrillators
Primary Prevention
Registries
Sudden Cardiac Death
Therapeutics
Adenosine Triphosphate
Equipment and Supplies
Observational Studies
Shock
Survival Rate
Prospective Studies
Survival

Keywords

  • Implantable cardioverter-defibrillator
  • Long-term outcome
  • Primary prevention
  • Sudden cardiac death

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Indication to cardioverter-defibrillator therapy and outcome in real world primary prevention. Data from the IRIDE [Italian registry of prophylactic implantation of defibrillators] study. / Proclemer, Alessandro; Muser, Daniele; Campana, Andrea; Zoni-Berisso, Massimo; Zecchin, Massimo; Locatelli, Alessandro; Brieda, Marco; Gramegna, Lorena; Santarone, Mauro; Chiodi, Leandro; Mazzone, Patrizio; Rebellato, Luca; Facchin, Domenico.

In: International Journal of Cardiology, Vol. 168, No. 2, 30.09.2013, p. 1416-1421.

Research output: Contribution to journalArticle

Proclemer, A, Muser, D, Campana, A, Zoni-Berisso, M, Zecchin, M, Locatelli, A, Brieda, M, Gramegna, L, Santarone, M, Chiodi, L, Mazzone, P, Rebellato, L & Facchin, D 2013, 'Indication to cardioverter-defibrillator therapy and outcome in real world primary prevention. Data from the IRIDE [Italian registry of prophylactic implantation of defibrillators] study', International Journal of Cardiology, vol. 168, no. 2, pp. 1416-1421. https://doi.org/10.1016/j.ijcard.2012.12.042
Proclemer, Alessandro ; Muser, Daniele ; Campana, Andrea ; Zoni-Berisso, Massimo ; Zecchin, Massimo ; Locatelli, Alessandro ; Brieda, Marco ; Gramegna, Lorena ; Santarone, Mauro ; Chiodi, Leandro ; Mazzone, Patrizio ; Rebellato, Luca ; Facchin, Domenico. / Indication to cardioverter-defibrillator therapy and outcome in real world primary prevention. Data from the IRIDE [Italian registry of prophylactic implantation of defibrillators] study. In: International Journal of Cardiology. 2013 ; Vol. 168, No. 2. pp. 1416-1421.
@article{587565a0a16349429d22a69a132ca9a4,
title = "Indication to cardioverter-defibrillator therapy and outcome in real world primary prevention. Data from the IRIDE [Italian registry of prophylactic implantation of defibrillators] study",
abstract = "Aims: Several trials demonstrated the life saving role of implantable cardioverter-defibrillators (ICD) in primary prevention of sudden cardiac death (SCD). The aim was to evaluate the clinical characteristics and 4-year outcome of consecutive patients treated in clinical practice by prophylactic ICD implantation on the basis of class I recommendations and up-to-date ICD programming. Methods and results: IRIDE multi-center, prospective and observational study enrolled 604 consecutive patients (mean age: 66±10 years) treated by ICD between 01/01/2006 and 30/06/2010. Main characteristics were similarly distributed among the inclusion criteria of MADIT II (24{\%}), SCD-HeFT (24{\%}), COMPANION (26{\%}) and MADIT-CRT (18{\%}) trials, while a small number of patients met the MUSTT and MADIT (7{\%}) inclusion criteria. Single-chamber ICDs were implanted in 168 (28{\%}) patients, dual-chamber in 167 (28{\%}) and biventricular in 269 (43{\%}) patients. ATP programming was activated in 546 (90{\%}) patients. Overall survival and rate of appropriate ICD intervention by ATP and/or shock at 12-24-36-48 months of follow-up were 94{\%}, 89{\%}, 80{\%}, 75{\%} and 16{\%}, 28{\%}, 37{\%} and 50{\%}, respectively. No difference inmortality rate between the groups who received or did not receive appropriate ICD interventions was demonstrated (p=ns). Conclusions: The IRIDE study confirms the effectiveness in real world practice of ICD implantation in patients at risk of SCD. The life saving role of ICD therapy increases as the duration of follow-up is prolonged and the survival benefit is similar in patients who received or did not receive appropriate device treatment, thus suggesting a beneficial effect of up-to-date device programming.",
keywords = "Implantable cardioverter-defibrillator, Long-term outcome, Primary prevention, Sudden cardiac death",
author = "Alessandro Proclemer and Daniele Muser and Andrea Campana and Massimo Zoni-Berisso and Massimo Zecchin and Alessandro Locatelli and Marco Brieda and Lorena Gramegna and Mauro Santarone and Leandro Chiodi and Patrizio Mazzone and Luca Rebellato and Domenico Facchin",
year = "2013",
month = "9",
day = "30",
doi = "10.1016/j.ijcard.2012.12.042",
language = "English",
volume = "168",
pages = "1416--1421",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Indication to cardioverter-defibrillator therapy and outcome in real world primary prevention. Data from the IRIDE [Italian registry of prophylactic implantation of defibrillators] study

AU - Proclemer, Alessandro

AU - Muser, Daniele

AU - Campana, Andrea

AU - Zoni-Berisso, Massimo

AU - Zecchin, Massimo

AU - Locatelli, Alessandro

AU - Brieda, Marco

AU - Gramegna, Lorena

AU - Santarone, Mauro

AU - Chiodi, Leandro

AU - Mazzone, Patrizio

AU - Rebellato, Luca

AU - Facchin, Domenico

PY - 2013/9/30

Y1 - 2013/9/30

N2 - Aims: Several trials demonstrated the life saving role of implantable cardioverter-defibrillators (ICD) in primary prevention of sudden cardiac death (SCD). The aim was to evaluate the clinical characteristics and 4-year outcome of consecutive patients treated in clinical practice by prophylactic ICD implantation on the basis of class I recommendations and up-to-date ICD programming. Methods and results: IRIDE multi-center, prospective and observational study enrolled 604 consecutive patients (mean age: 66±10 years) treated by ICD between 01/01/2006 and 30/06/2010. Main characteristics were similarly distributed among the inclusion criteria of MADIT II (24%), SCD-HeFT (24%), COMPANION (26%) and MADIT-CRT (18%) trials, while a small number of patients met the MUSTT and MADIT (7%) inclusion criteria. Single-chamber ICDs were implanted in 168 (28%) patients, dual-chamber in 167 (28%) and biventricular in 269 (43%) patients. ATP programming was activated in 546 (90%) patients. Overall survival and rate of appropriate ICD intervention by ATP and/or shock at 12-24-36-48 months of follow-up were 94%, 89%, 80%, 75% and 16%, 28%, 37% and 50%, respectively. No difference inmortality rate between the groups who received or did not receive appropriate ICD interventions was demonstrated (p=ns). Conclusions: The IRIDE study confirms the effectiveness in real world practice of ICD implantation in patients at risk of SCD. The life saving role of ICD therapy increases as the duration of follow-up is prolonged and the survival benefit is similar in patients who received or did not receive appropriate device treatment, thus suggesting a beneficial effect of up-to-date device programming.

AB - Aims: Several trials demonstrated the life saving role of implantable cardioverter-defibrillators (ICD) in primary prevention of sudden cardiac death (SCD). The aim was to evaluate the clinical characteristics and 4-year outcome of consecutive patients treated in clinical practice by prophylactic ICD implantation on the basis of class I recommendations and up-to-date ICD programming. Methods and results: IRIDE multi-center, prospective and observational study enrolled 604 consecutive patients (mean age: 66±10 years) treated by ICD between 01/01/2006 and 30/06/2010. Main characteristics were similarly distributed among the inclusion criteria of MADIT II (24%), SCD-HeFT (24%), COMPANION (26%) and MADIT-CRT (18%) trials, while a small number of patients met the MUSTT and MADIT (7%) inclusion criteria. Single-chamber ICDs were implanted in 168 (28%) patients, dual-chamber in 167 (28%) and biventricular in 269 (43%) patients. ATP programming was activated in 546 (90%) patients. Overall survival and rate of appropriate ICD intervention by ATP and/or shock at 12-24-36-48 months of follow-up were 94%, 89%, 80%, 75% and 16%, 28%, 37% and 50%, respectively. No difference inmortality rate between the groups who received or did not receive appropriate ICD interventions was demonstrated (p=ns). Conclusions: The IRIDE study confirms the effectiveness in real world practice of ICD implantation in patients at risk of SCD. The life saving role of ICD therapy increases as the duration of follow-up is prolonged and the survival benefit is similar in patients who received or did not receive appropriate device treatment, thus suggesting a beneficial effect of up-to-date device programming.

KW - Implantable cardioverter-defibrillator

KW - Long-term outcome

KW - Primary prevention

KW - Sudden cardiac death

UR - http://www.scopus.com/inward/record.url?scp=84885321151&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885321151&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2012.12.042

DO - 10.1016/j.ijcard.2012.12.042

M3 - Article

VL - 168

SP - 1416

EP - 1421

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

IS - 2

ER -